Cassava Sciences (SAVA) said late Tuesday that it is reducing its workforce by ten employees, laying off 33% of its workforce in Q1, incurring one-time expenses of $400,000 for the reduction.
The clinical-stage company said it will reduce expenses by halting the planned biomarker analysis of additional plasma samples from previous mid-stage studies of its investigational potential treatments for central nervous system diseases including Alzheimer's disease.
The measures come after the company said a late-stage study of its drug simufilam as a potential treatment for Alzheimer's patients did not meet its endpoints.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。